Teva acquires Mexico’s Rimsa for $2.3 billion
pharmafile | October 5, 2015 | News story | Research and Development, Sales and Marketing | Mexico, Rimsa, Teva, mergers and acquisitions
Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market
Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand and Commercial Presence and Loyal Customer Base
Teva has acquired leading Mexican pharma company Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for $2.3 billion.
Through this acquisition, Israel-based Teva says it will become a leading pharmaceutical company in Mexico: the second largest market in Latin America and one of the top five emerging markets globally.
Teva said it expects the deal to yield substantial and achievable synergies and offer a platform for growth in the region.
Erez Vigodman, president and CEO of Teva, says: “This acquisition delivers on our strategy of increasing our presence in key emerging markets in order to position Teva for long-term growth in these markets. Rimsa will provide Teva with a significant platform for growth by combining the strong Rimsa brand, licensed portfolio of differentiated, patent-protected products, promising pipeline, significant relationships with physicians, patients and healthcare providers and its strong commercial presence.
“The combination of our companies lays the foundation for a leadership position and high long-term, profitable and sustainable growth in the region and further reinforces our commitment to innovation, quality and improving the health of people worldwide.”
Rimsa achieved revenue in 2014 of $227 million with an annual growth, year over year of 10.6% since 2011. The company has an extensive portfolio of specialty products, including fixed-dose combination products which have fueled its growth. Rimsa’s well-established sales footprint is expected to provide a platform for additional Teva products.
“For 45 years, Rimsa has operated as a leading pharmaceutical company in Mexico, the second largest healthcare market in Latin America, with a high growth, unique and diversified business model. We share Teva’s focus on providing quality healthcare and we are excited to become a part of Teva in meeting the needs of a population of 120 million,” comments Luis Jorge Pérez Juárez, CEO of Rimsa.
“In addition to this unique portfolio of patent-protected products, Rimsa differentiates itself as a leading provider of branded specialty drugs, including fixed-dose combinations, which increase adherence and reduce overall costs to patients,” adds Siggi Olafsson, president and CEO of Teva Global Generic Medicines. “We will build on their brand reputation, successful sales force model, well-established commercial footprint and loyal customer base to introduce additional specialty and generic Teva medicines to patients in Mexico and across the region.”
The acquisition was unanimously approved by Teva’s Board of Directors, led by the Chairman, Yitzhak Peterburg. Teva said it expects to close these transactions by early first quarter, 2016.
Joel Levy
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
Mexico to hold trials for Chinese and American COVID-19 vaccines
Mexico aims to conduct late stage trials for coronavirus vaccines designed by US and Chinese …
